Savira pharmaceuticals GmbH was founded in July 2009 by the European Molecular Biology Laboratory (EMBL), onepharm Research and Development GmbH, private investors, and management. Led by CEO Oliver Szolar and CSO Helmut Buschmann, a seasoned management team combines scientific, technological, and business experience in the pharmaceutical industry.
R&D:Savira is dedicated to the development of novel, innovative anti-influenza therapeutics following a rational, structure-based design approach.
Mooslackengasse 17, Büro 2119
1190 Vienna
Vienna
Contact: Oliver Szolar (CEO)
Telephone: +43 (1) 25077-5904
Email: office@savira.at
Website